A Search Service for Abbreviation / Long Form

â–  Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 55
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : IXE
Long Form : ixekizumab
No. Year Title Co-occurring Abbreviation
2023 Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons. ADA, ASAS, ASDAS, BASFI, bDMARDs, CRP, CZP, ETN, ITC, MRI, OSI, SEC, SLR
2023 Economic Evaluation of Selected Interleukin Inhibitors Versus Methotrexate for Moderate-to-Severe Plaque Psoriasis, From the Philippine Payer Perspective. GoP, ICERs, ILIs, MTX, PHP, SEC
2023 Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program. IR, PY, TEAEs
2023 Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience. AEs, DMARDs, HR, PsA
2022 Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52Weeks: Data from Three PhaseIII Randomised Controlled Trials. nr-axSpA, r-axSpA
2022 Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). CI, DLQI, FMA, IL, OR, PSoHO, sPGA
2022 Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. bDMARD
2022 Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months. ICER, PPPM, SEC
2022 Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings. ADA, HCRU, ICER
10  2022 Ixekizumab four-week dosing is comparable to two-week dosing in psoriasis patients and reduces treatment costs: experience in a real-world setting over a 12-week period DLQI, PASI
11  2022 Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study. ADA, IPTW
12  2022 Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan® Databases. ADA, ETN, IPTW, SEC, UST
13  2022 Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study. ASDAS, OL, RWRP
14  2022 The effect of therapy on TRM in psoriatic lesions. ADA, MTX, SEC, TRM
15  2021 Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis. axSpA, SEC
16  2021 Comparing the efficacy and safety of IL-17 inhibitors for treatment of moderate-to-severe psoriasis: a randomized double blind pilot study with a review of literature. AEs, DLQI, IL-17A, PASI, PGA, SEC
17  2021 Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18Months. PDC, SEC
18  2021 Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). ASDAS, axSpA, COAST-Y, PBO, RWRP
19  2021 Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population. ADA, CER, ETA, GUS, PDC, SEC, UST
20  2021 Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post-hoc Analysis from a Long-term Clinical Study. DLQI, HRQoL, IL, PASI, UST
21  2021 Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors. DAPSA, DAS28-CRP, EULAR, HAQ-DI, MDA, PBO, TNFi
22  2021 Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis. EU, US
23  2021 Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies. ACR, MTX, PsA
24  2021 Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice. ADA, SEC
25  2021 Real-World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study. ICER, PDC, PPPM, PsA
26  2021 Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years. mSASSS, r-axSpA
27  2021 Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2). DLQI, NAPSI, PPASI, PSSI
28  2021 T cell functions of psoriatic arthritis patients are regulated differently by TNF, IL-17A and IL-6 receptor blockades in vitro. ADA, IL-17A, IL-6R, PBMCs, PHA, TCZ, TNF-alpha
29  2021 Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population. ADA, CER, ETA, GUS, PsA, PsO, SEC, UST
30  2020 Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). sPGA 0,1
31  2020 Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naive Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study. ADA, csDMARDs, MTX, PsA
32  2020 Interleukin-17 Inhibitors for the Treatment of Ankylosing Spondylitis. AS, bDMARDs, BKZ, SEC, TNFi
33  2020 Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). NAPSI, PASI, UST
34  2020 Ixekizumab for the treatment of ankylosing spondylitis. AS
35  2020 Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. ADA, bDMARD, EQ-5D-5L, PBO, r-axSpA, TNFi
36  2020 Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. ---
37  2020 Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52. ACR, ADA, csDMARD, PASI, PsA, Wk
38  2020 Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis. HAQ-DI, NRS, PROs, PsA, VAS
39  2020 Short-term effectiveness of ixekizumab to refractory psoriatic arthritis with spondyloarthritis: two case reports. PsA
40  2019 A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. ADA, csDMARDs, PsA
41  2019 Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab. ADA, ICER, IPTW, PMPM, PsO, SEC
42  2019 Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis. ADA, DLQI, FAE, INF, MID, MTX, PASI, SEC
43  2019 Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial. AUC, DLQI, Itch NRS, PASI, UST
44  2019 Ixekizumab for treating ankylosing spondylitis. axSpA, IL-17i, TNFi
45  2019 Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. MI, mNRI
46  2018 A review of ixekizumab in the treatment of psoriatic arthritis. csDMARDs, IgG4, PsA, TNFi
47  2018 Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open-label Study of Patients with Moderate-to-severe Plaque Psoriasis. Itch NRS, PASI, PatGA, sPGA
48  2018 Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies. ETN, NRS, PASI, PBO
49  2018 Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study. PASI
50  2017 Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. DLQI, IL, NRS, sPGA, UST
51  2017 Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. PBO, sPGA
52  2017 Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). ACR, ADA, EPP, PBO, PsA
53  2017 Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials. ETN, HRQoL, PASI
54  2017 Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials. DLQI, ETN, PRD
55  2017 Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants. CI, IL